A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
← catalyst calendarSponsored by AnaptysBio, Inc. (industry) · ANAB — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
420estimated
Sites
92
Countries
Belgium, Canada, Estonia +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-31 | actual | When the study began enrolling |
| Primary completion | 2024-11-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Interventions
- Drug: Rosnilimab — also filed as ANB030
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMean change from Baseline in 28-Joint Disease Activity Score based on CRP (DAS28-CRP) at Week 12
measured Baseline to Week 12
Permalink · ANAB's whole pipeline · Catalyst calendar · Every registered study · What changed